The Study to Evaluate the Safety and Efficacy of the Onyx Family

Inclusion Criteria: * Aged 75 or more. * Eligible for interventional procedures. * Evidence of myocardial ischemia or coronary artery stenosis ≥ 50%. * Able to take antiplatelets for at least 1 months after the procedure. * Patients who underwent coronary artery procedures with ZES (Medtronic, Minneapolis, MN, Onyx™ family) stent. Exclusion Criteria: * The patient has a known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, zotarolimus, and contrast media (patients with documented sensitivity to contrast media which can be effectively premedicated with steroids and diphenhydramine \[eg, rash\] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled). * Patients with active pathologic bleeding. * Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months. * History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia). * Noncardiac comorbid conditions are present with life expectancy \<1 year or that may result in protocol noncompliance (per site investigator\'s medical judgment). * Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.